NKY(SZ:300109)2019-04-25 16:00Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 15% year-over-year growth[19]. - The company reported a total revenue of 1.2 billion RMB for the fiscal year 2018, representing a year-over-year growth of 15%[55]. - The company reported a gross margin of 60%, maintaining strong profitability despite increased competition in the market[19]. - The company reported a gross margin of 45% for 2018, maintaining a stable margin compared to the previous year[55]. - The company reported a net profit attributable to shareholders decreased by 3.53% to ¥89,546,168.64 in 2018 from ¥92,823,189.13 in 2017[27]. - The net profit after deducting non-recurring gains and losses was ¥88,438,939.65, down 2.35% from ¥90,563,694.41 in the previous year[27]. - The company reported a basic earnings per share of ¥0.41, a decrease of 2.38% from ¥0.42 in 2017[27]. - The company reported a significant decline in revenue from PVP-I, which dropped by 73.11% to ¥21.97 million[80]. - The company reported a total revenue of 9,220 million RMB, with a net profit of 2,522.25 million RMB, reflecting a growth of 79.2%[110]. Market Expansion and Strategy - The company has been actively expanding its overseas market presence, which may introduce risks related to cultural differences and exchange rates[10]. - The company is actively pursuing market expansion, with plans to enter three new international markets by Q3 2024[22]. - The company aims to expand its market presence in both fine chemicals and precision medicine sectors, leveraging its technological advancements[36]. - The company is focusing on expanding its market presence in tumor screening and precision medication[110]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[46]. - The company is focusing on the dual-platform strategy of "consumer specialty chemicals platform + health care services platform" to maintain its leading position in the industry[127]. Research and Development - The company has invested in new technologies and product development, focusing on PVP series products and their applications[5]. - Research and development expenses increased by 20%, reflecting the company's commitment to innovation and technology advancement[21]. - The company has initiated a partnership with a leading pharmaceutical company to co-develop new therapeutic solutions, expected to launch in 2025[22]. - The company has developed new products and technologies in the fields of medical diagnostics and environmental protection, focusing on research and development[50]. - The company has filed for 10 new patents in 2018, focusing on innovative medical technologies and devices[55]. - The company is focusing on the development of a 10X Genomics service platform to enhance sequencing capabilities[95]. - The company is advancing the development of a multi-molecular marker liquid biopsy detection kit for breast cancer, with a completion target set for December 2019[93]. Environmental and Safety Management - The company has completed the "coal-to-gas" project and the recycled water reuse project, enhancing its environmental management capabilities[7]. - The company has increased its efforts in environmental protection, responding to stricter regulations since the implementation of the new Environmental Protection Law in 2015[6]. - The company is committed to optimizing its energy system and improving waste treatment processes to align with national environmental goals[7]. - The company has established a comprehensive safety production management system to mitigate risks associated with hazardous materials used in its products[5]. - The company has implemented a "dual prevention mechanism" for safety management, with no major safety incidents reported during the reporting period[5]. Talent and Human Resources - The company emphasizes the importance of retaining and attracting high-quality technical talent to maintain its innovation and development capabilities[9]. - The company is focusing on talent development, emphasizing a diverse management team and a comprehensive talent training system[73]. - The number of R&D personnel remained stable at 196, accounting for 24.84% of the total workforce[97]. Intellectual Property and Trademarks - The company holds a total of 30 patents as of December 31, 2018, primarily in practical new models related to medical and chemical technologies[52]. - The company has trademarks for raw materials and preservatives, indicating a focus on pharmaceutical and medical applications[45]. - The company is actively pursuing intellectual property protection to enhance its market position in the healthcare and personal care industries[45]. Financial Commitments and Shareholder Relations - The company reported a profit distribution plan to distribute a cash dividend of 1.00 RMB per 10 shares (including tax) based on a total of 217,936,025 shares[11]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during its growth phase, despite significant capital expenditure plans[146]. - The company declared cash dividends of 21,793,602.50 CNY for the year 2018, representing 24.34% of the net profit attributable to ordinary shareholders[148]. - The company has established a compensation mechanism for shareholders if performance targets are not achieved, ensuring accountability[157]. Acquisitions and Partnerships - A strategic acquisition of a biotechnology firm was completed, enhancing the company's capabilities in molecular diagnostics and expected to contribute an additional 200 million RMB in revenue[19]. - The company is undergoing a significant asset restructuring involving BioVision Inc., which specializes in the research, production, and sales of diagnostic reagents[196]. - The company has initiated a strategic acquisition of a local biotech firm to enhance its R&D capabilities and product offerings[55]. - The company has established partnerships with Karolinska Institute in Sweden and Heidelberg University in Germany to develop a breast cancer liquid biopsy project, enhancing its capabilities in female malignant tumor detection[38]. Compliance and Governance - The company has not faced any major litigation or arbitration matters during the reporting period[173]. - The company has not issued any non-standard audit reports for the reporting period[170]. - The company is actively managing its financial obligations and commitments to ensure compliance with regulatory requirements[160].